After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
We received an updated WNV package insert; please note the manufacturer and license number has been ...